Please use this identifier to cite or link to this item: http://www.repositorio.ufop.br/handle/123456789/4183
Title: In vitro and in vivo experimental models for drug screening and development for Chagas disease.
Authors: Romanha, Alvaro José
Castro, Solange Lisboa de
Soeiro, Maria de Nazaré Correia
Vieira, Joseli Lannes
Ribeiro, Isabela
Silva, André Talvani Pedrosa da
Bourdin, Bernadette
Blum, Bethania
Olivieri, Bianca
Zani, Carlos Leomar
Spadafora, Carmenza
Chiari, Egler
Chatelain, Eric
Chaves, Gabriela
Calzada, José Eduardo
Bustamante, Juan Manuel
Freitas Junior, Lucio Holanda Godim de
Romero, Luz I.
Bahia, Maria Terezinha
Lotrowska, Michel
Soares, Milena Botelho Pereira
Andrade, Sonia Gumes
Lotrowska, Tanya
Degrave, Wim
Andrade, Zilton de Araújo
Keywords: Trypanosoma cruzi
Chagas disease treatment
Drug screening
Benznidazole
Issue Date: 2010
Citation: ROMANHA, A. J. et al. In vitro and in vivo experimental models for drug screening and development for Chagas disease. Memórias do Instituto Oswaldo Cruz, v. 105, p. 233-238, 2010. Disponível em: <http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762010000200022&lng=en&nrm=iso&tlng=en>. Acesso em: 08 nov. 2014.
Abstract: Chagas disease, a neglected illness, affects nearly 12-14 million people in endemic areas of Latin America. Al¬though the occurrence of acute cases sharply has declined due to Southern Cone Initiative efforts to control vector transmission, there still remain serious challenges, including the maintenance of sustainable public policies for Chagas disease control and the urgent need for better drugs to treat chagasic patients. Since the introduction of benznidazole and nifurtimox approximately 40 years ago, many natural and synthetic compounds have been as¬sayed against Trypanosoma cruzi, yet only a few compounds have advanced to clinical trials. This reflects, at least in part, the lack of consensus regarding appropriate in vitro and in vivo screening protocols as well as the lack of biomarkers for treating parasitaemia. The development of more effective drugs requires (i) the identification and validation of parasite targets, (ii) compounds to be screened against the targets or the whole parasite and (iii) a panel of minimum standardised procedures to advance leading compounds to clinical trials. This third aim was the topic of the workshop entitled Experimental Models in Drug Screening and Development for Chagas Disease, held in Rio de Janeiro, Brazil, on the 25th and 26th of November 2008 by the Fiocruz Program for Research and Technological Development on Chagas Disease and Drugs for Neglected Diseases Initiative. During the meeting, the minimum steps, requirements and decision gates for the determination of the efficacy of novel drugs for T. cruzi control were evaluated by interdisciplinary experts and an in vitro and in vivo flowchart was designed to serve as a general and standardised protocol for screening potential drugs for the treatment of Chagas disease.
URI: http://www.repositorio.ufop.br/handle/123456789/4183
metadata.dc.identifier.doi: http://dx.doi.org/10.1590/S0074-02762010000200022
ISSN: 0074-0276
metadata.dc.rights.license: O periódico Memórias do Instituto Oswaldo Cruz permite que o Repositório Institucional da Universidade Federal de Ouro Preto (UFOP) deposite uma cópia eletrônica dos artigos publicados por esse periódico  em que ao menos um dos autores faça parte da comunidade cientifica da UFOP. Fonte: Licença concedida mediante prenchimento de formulário enviado no dia 12 dez. 2013.
Appears in Collections:DECBI - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
ARTIGO_VitroVivoExperimental.pdf408,05 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.